BDBM305806 N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclobutyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)-1H-pyrazol-5-yl)acetamide::US10144738, Example 5::US10822341, Example 5::US11472809, Example 5

SMILES CO[C@H]1C[C@@](CC#N)(C1)n1cc(cn1)-c1nc(cn2nccc12)-c1cc(NC(C)=O)[nH]n1

InChI Key

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 305806   

TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  35nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  472nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  35nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  1.92E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  472nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  35nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  1.92E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  472nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  35nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  1.92E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  472nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305806(N-(3-(4-(1-((1r,3s)-1-(Cyanomethyl)-3-methoxycyclo...)
Affinity DataIC50:  1.92E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent